ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,960,930 | +94.0% | 956,556 | +119.7% | 0.06% | +56.1% |
| Q2 2023 | $13,382,044 | -27.8% | 435,330 | -15.4% | 0.04% | -46.1% |
| Q1 2023 | $18,544,965 | +63.4% | 514,709 | +79.2% | 0.08% | +68.9% |
| Q4 2022 | $11,352,871 | +206.9% | 287,269 | +212.1% | 0.04% | +136.8% |
| Q3 2022 | $3,699,000 | -50.4% | 92,055 | -48.1% | 0.02% | -53.7% |
| Q2 2022 | $7,451,000 | +5.9% | 177,240 | -1.9% | 0.04% | +36.7% |
| Q1 2022 | $7,038,000 | -52.1% | 180,653 | -51.0% | 0.03% | -23.1% |
| Q4 2021 | $14,706,000 | +72.0% | 369,028 | +56.0% | 0.04% | +56.0% |
| Q3 2021 | $8,550,000 | +18.4% | 236,593 | +34.3% | 0.02% | -7.4% |
| Q2 2021 | $7,220,000 | +1035.2% | 176,152 | +1108.0% | 0.03% | +575.0% |
| Q1 2021 | $636,000 | -40.1% | 14,582 | -31.2% | 0.00% | -50.0% |
| Q4 2020 | $1,061,000 | -89.1% | 21,193 | -89.4% | 0.01% | -94.9% |
| Q2 2020 | $9,710,000 | – | 200,000 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |